Comparative Experimental Study Between Bupivacaine and Ropivacaine Regarding Efficacy in Third Molar Removal Surgery Under General Anesthesia

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07108465

Enrollment

Registered

2025-08-07

Start date

2025-07-01

Completion date

2025-12-31

Last updated

2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Third Molars Extraction

Brief summary

The goal of this clinical trial is to compare the efficacy of bupivacaine and ropivacaine in third molar removal surgery under general anesthesia in healthy volunteers. The main question aims to determine whether there is any difference in vital signs, hemostasis and postoperative pain between ropivacaine and bupivacaine in patients undergoing third molars extraction under general anesthesia. Researchers will compare bupivacaine and ropivacaine in a split-mouth study to determine if one drug is more effective in third molar extraction surgery under general anesthesia (better hemostasis, less postoperative pain, and fewer changes in vital signs). Participants will undergo a single surgical procedure and complete the Visual Analog Scale to record postoperative pain

Interventions

DRUGBupivacaine 0,5%

Injection of bupivacaine 0,5% in group A

DRUGRopivacaine 0,75%

Injection of ropivacaine 0,75% in group B

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients aged 18 to 60 * Patients ASA Physical Status Classification I and II * Patients with impacted or semi-impacted lower third molars with similar positioning on both sides according to the Pell and Gregory classification

Exclusion criteria

* Patients who can have surgery under local anesthesia * Patients where more procedures are required in the same surgical session

Design outcomes

Primary

Measure	Time frame	Description
Evaluate if there is a significant difference between groups in postoperative analgesic capacity using Visual Analog Scale, intraoperative hemostasis and in vital signs during anesthesia.	From surgery to 7 postoperative days	The Visual Analog Scale (0-10 VAS) can be interpreted as no pain (0), mild (1-3), moderate (4-6),severe (7-9),or worse pain (10)

Countries

Brazil

Contacts

Primary ContactHenrique T Oliveira

htedesco99@gmail.com55 51999601939

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026